Glibenclamid Fabra en es it fr

Glibenclamid Fabra Brand names, Glibenclamid Fabra Analogs

Glibenclamid Fabra Brand Names Mixture

  • No information avaliable

Glibenclamid Fabra Chemical_Formula


Glibenclamid Fabra RX_link

Glibenclamid Fabra fda sheet

Glibenclamid Fabra msds (material safety sheet)

Glibenclamid_Fabra MSDS

Glibenclamid Fabra Synthesis Reference

Weber et al., U.S. Pat. 3,454,635 (1969)

Glibenclamid Fabra Molecular Weight

494.004 g/mol

Glibenclamid Fabra Melting Point


Glibenclamid Fabra H2O Solubility

4 mg/L

Glibenclamid Fabra State


Glibenclamid Fabra LogP


Glibenclamid Fabra Dosage Forms

Tablet (1.25 mg, 2.5 mg, 5 mg)

Glibenclamid Fabra Indication

Indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.

Glibenclamid Fabra Pharmacology

Glyburide, a second-generation sulfonylurea antidiabetic agent, appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonyl-urea hypoglycemic drugs. The combination of glyburide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms. In addition to its blood glucose lowering actions, glyburide produces a mild diuresis by enhancement of renal free water clearance. Glyburide is twice as potent as the related second-generation agent glipizide.

Glibenclamid Fabra Absorption

Significant absorption within 1 hour and peak plasma levels are reached within 4 hours.

Glibenclamid Fabra side effects and Toxicity

Oral rat LD50: > 20,000 mg/kg. Oral mouse LD50: 3250 mg/kg.

Glibenclamid Fabra Patient Information

Patients should be informed of the potential risks and advantages of MICRONASE and of alternative modes of therapy. They also should be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose.

The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure also should be explained.

Glibenclamid Fabra Organisms Affected

Humans and other mammals